The Synergistic Immunoregulatory Effects of Culture-Expanded Mesenchymal Stromal Cells and CD4+25+Foxp3+ Regulatory T Cells on Skin Allograft Rejection

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lee, Jung Ho ^a,b   Jeon, Eun Joo ^a   Kim, Nayoun ^a   Nam, Young Sun ^a   Im, Keon Il ^a   Lim, Jung Yeon ^a   Kim, Eun Jung ^a   Cho, Mi La ^c   Han, Ki Taik ^b   Cho, Seok Goo ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Korean Institute of Radiological and Medical Sciences   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

STAT PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; CELL FUNCTION; CELL TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; SPLEEN CELL; STEM CELL EXPANSION; SURVIVAL RATE; TH2 CELL; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 84881104041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070968     Document Type: Article

References (47)

1. Dubernard JM, Owen E, Herzberg G, Lanzetta M, Martin X, et al. (1999) Human hand allograft: report on first 6 months. Lancet 353: 1315-1320.
2. Dubernard JM, Lengele B, Morelon E, Testelin S, Badet L, et al. (2007) Outcomes 18 months after the first human partial face transplantation. N Engl J Med 357: 2451-2460.
3. Lanzetta M, Petruzzo P, Vitale G, Lucchina S, Owen ER, et al. (2004) Human hand transplantation: what have we learned? Transplant Proc 36: 664-668.
4. Petruzzo P, Revillard JP, Kanitakis J, Lanzetta M, Hakim NS, et al. (2003) First human double hand transplantation: efficacy of a conventional immunosuppressive protocol. Clin Transplant 17: 455-460.
5. Brenner MJ, Tung TH, Jensen JN, Mackinnon SE, (2002) The spectrum of complications of immunosuppression: is the time right for hand transplantation? J Bone Joint Surg Am 84-A: 1861-1870.
6. Siemionow M, Agaoglu G, (2006) Controversies following the report on transplantation of cephalocervical skin flap. Plast Reconstr Surg 118: 268-270.
7. Majzoub RK, Cunningham M, Grossi F, Maldonado C, Banis JC, et al. (2006) Investigation of risk acceptance in hand transplantation. J Hand Surg Am 31: 295-302.
8. Brouha P, Naidu D, Cunningham M, Furr A, Majzoub R, et al. (2006) Risk acceptance in composite-tissue allotransplantation reconstructive procedures. Microsurgery 26: 144-149; discussion 149-150.
9. Horner BM, Randolph MA, Huang CA, Butler PE, (2008) Skin tolerance: in search of the Holy Grail. Transpl Int 21: 101-112.
10. Gorantla VS, Schneeberger S, Brandacher G, Sucher R, Zhang D, et al. (2010) T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) 24: 147-159.
11. Noel D, Djouad F, Bouffi C, Mrugala D, Jorgensen C, (2007) Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 48: 1283-1289.
12. McCurry KR, Colvin BL, Zahorchak AF, Thomson AW, (2006) Regulatory dendritic cell therapy in organ transplantation. Transpl Int 19: 525-538.
13. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843.
14. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, et al. (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367-372.
15. Aggarwal S, Pittenger MF, (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
16. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729.
17. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, et al. (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390-1397.
18. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48.
19. Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, et al. (2008) Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 300: 115-124.
20. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, et al. (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
21. Griffin MD, Ritter T, Mahon BP, (2010) Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21: 1641-1655.
22. Soleimani M, Nadri S, (2009) A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 4: 102-106.
23. Jeon EJ, Yoon BY, Lim JY, Oh HJ, Park HS, et al. (2012) Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity 45: 460-469.
24. Devauchelle B, Badet L, Lengele B, Morelon E, Testelin S, et al. (2006) First human face allograft: early report. Lancet 368: 203-209.
25. Rose KG, Sesterhenn K, Wustrow F, (1979) Tracheal allotransplantation in man. Lancet 1: 433.
26. Doi K, Kawai S, Shigetomi M, (1996) Congenital tibial pseudoarthrosis treated with vascularised bone allograft. Lancet 347: 970-971.
27. Hettiaratchy S, Randolph MA, Petit F, Lee WP, Butler PE, (2004) Composite tissue allotransplantation- a new era in plastic surgery? Br J Plast Surg 57: 381-391.
28. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, et al. (2008) Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 358: 362-368.
29. Hutchinson JA, Brem-Exner BG, Riquelme P, Roelen D, Schulze M, et al. (2008) A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 21: 742-754.
30. Golshayan D, Wyss JC, Abulker CW, Schaefer SC, Lechler RI, et al. (2009) Transplantation tolerance induced by regulatory T cells: in vivo mechanisms and sites of action. Int Immunopharmacol 9: 683-688.
31. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, et al. (2009) Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 9: 1760-1772.
32. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, et al. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621.
33. Rasmusson I, (2006) Immune modulation by mesenchymal stem cells. Exp Cell Res 312: 2169-2179.
34. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755-1761.
35. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, et al. (2005) Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19: 1597-1604.
36. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, et al. (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219.
37. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, et al. (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90: 516-525.
38. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, et al. (2006) Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81: 1589-1595.
39. Field EH, Gao Q, Chen NX, Rouse TM, (1997) Balancing the immune system for tolerance: a case for regulatory CD4 cells. Transplantation 64: 1-7.
40. Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Muller A, et al. (2001) Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 107: 909-916.
41. Tay SS, Plain KM, Bishop GA, (2009) Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 14: 16-22.
42. Velásquez-Lopera MM, Eaton VL, Lerret NM, Correa LA, Decresce RP, et al. (2008) Induction of transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+) regulatory T cells. Transpl Immunol 19: 127-135.
43. Adeegbe D, Levy RB, Malek TR, (2010) Allogeneic T regulatory cell-mediated transplantation tolerance in adoptive therapy depends on dominant peripheral suppression and central tolerance. Blood 115: 1932-1940.
44. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, et al. (2009) Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 106: 1903-1908.
45. Schliesser U, Streitz M, Sawitzki B, (2012) Tregs: application for solid-organ transplantation. Curr Opin Organ Transplant 17: 34-41.
46. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S, (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105: 10113-10118.
47. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L, (2003) Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 171: 3435-3441.